Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -4.93
- Piotroski Score 4.00
- Grade Neutral
- Symbol (VERO)
- Company Venus Concept Inc.
- Price $0.60
- Changes Percentage (-15.49%)
- Change -$0.11
- Day Low $0.59
- Day High $0.72
- Year High $2.43
Venus Concept Inc., a medical technology company, develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies, and related services in the United States and internationally. Its product portfolio includes aesthetic device platforms, including Venus Legacy, a noninvasive device used in dermatological and general surgical procedures for females; Venus Versa, a multi-application device used in aesthetic and cosmetic procedures; and Venus Viva, an advanced, portable, and fractional RF system for dermatological procedures requiring ablation and resurfacing of the skin. The company also offers Venus Fiore, a device that delivers non-thermal RF with massage and magnetic field pulses to treat various medical conditions; Venus Bliss, a device for non-invasive lipolysis of the abdomen and flanks in individuals with a body mass index of 30 or less; Venus Glow, a dermabrasion device used to improve skin appearance; and NeoGraft, an advanced hair restoration technology with an automated FUE and implantation system. In addition, it provides Venus Velocity and Venus Epileve for hair removal, permanent hair reduction, and treatment of pseudofolliculitis barbae; and ARTAS iX, a robotic system to assist physicians in identifying and extracting hair follicles units from the scalp during hair transplantation, creating recipient sites, and implanting the harvested hair follicles. The company is headquartered in Toronto, Canada.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/11/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$6.68
- Trailing P/E Ratio -0.14
- Forward P/E Ratio -0.14
- P/E Growth -0.14
- Net Income $-37,250,000
Income Statement
Quarterly
Annual
Latest News of VERO
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Will Ferrell's Netflix doc Will & Harper is flawed but vital viewing for cis people | Veronica Esposito
The road trip documentary "Will & Harper" explores the journey of comedian Will Ferrell and his transgender friend, Harper Steele, as they navigate friendship and transition. It delves into uncomforta...
By The Guardian | 20 hours ago -
Kristen Bell Would Do a Reboot of Veronica Mars or The Good Place 'Any Day': 'Never Wanted Them to End' (Exclusive)
The actress, 44, is open to reviving her beloved shows, Veronica Mars and The Good Place. She stars in Netflix's series Nobody Wants This, playing an agnostic sex podcaster who falls for a Rabbi....
By PEOPLE.com | 1 day ago -
Insider Sale: CFO Mark Hahn Sells 600,000 Shares of Verona Pharma PLC (VRNA)
On September 11, 2024, Verona Pharma PLC's CFO, Mark Hahn, sold 600,000 shares, now owning 14,339,688 shares. The biopharmaceutical company focuses on respiratory disease therapies....
By Yahoo! Finance | 2 weeks ago
